Comparison of fondaparinux and enoxaparin in acute coronary syndromes

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Acute coronary syndromes (ACS) management involves balancing antithrombotic therapy to prevent ischemic events against the risk of bleeding.
• Current treatments combining anticoagulants, antiplatelet agents, and invasive procedures increase bleeding complications.
• Assessing alternative anticoagulants like fondaparinux is crucial for optimizing ACS patient care.

Purpose of the Study:

• To compare the efficacy and safety of fondaparinux versus enoxaparin in patients with ACS.
• To determine if fondaparinux could maintain anti-ischemic benefits while reducing bleeding compared to enoxaparin.

Main Methods:

• A randomized trial involving 20,078 ACS patients assigned to receive either fondaparinux or enoxaparin.
• Primary outcome: death, myocardial infarction, or refractory ischemia at nine days.
• Secondary outcomes: major bleeding, composite outcomes, and long-term mortality/morbidity followed up to six months.

Main Results:

• Fondaparinux was non-inferior to enoxaparin for the primary ischemic outcome at nine days (5.8% vs. 5.7%).
• Major bleeding rates were significantly lower with fondaparinux (2.2% vs. 4.1%, P<0.001).
• Fondaparinux showed a trend towards fewer ischemic events at 30 days and study end, and significantly reduced mortality at 30 and 180 days.

Conclusions:

• Fondaparinux offers comparable anti-ischemic protection to enoxaparin in ACS patients.
• Fondaparinux substantially reduces major bleeding complications.
• The findings support fondaparinux as a favorable treatment option, improving long-term outcomes in ACS.